Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 105.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 376,161 shares of the biopharmaceutical company's stock after acquiring an additional 193,296 shares during the period. Schroder Investment Management Group owned 0.41% of Ultragenyx Pharmaceutical worth $15,900,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $40,463,000. Pictet Asset Management Holding SA boosted its stake in Ultragenyx Pharmaceutical by 125.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock worth $49,375,000 after buying an additional 653,088 shares during the period. Two Sigma Advisers LP increased its position in shares of Ultragenyx Pharmaceutical by 123.4% during the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company's stock valued at $54,872,000 after acquiring an additional 545,600 shares during the last quarter. Fisher Asset Management LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $11,156,000. Finally, Prudential Financial Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 659.5% in the 4th quarter. Prudential Financial Inc. now owns 272,940 shares of the biopharmaceutical company's stock valued at $11,483,000 after acquiring an additional 237,003 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

Remove Ads

Insider Activity

In other news, CEO Emil D. Kakkis sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the transaction, the chief executive officer now directly owns 2,158,985 shares in the company, valued at approximately $91,713,682.80. This trade represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Howard Horn sold 1,785 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the sale, the chief financial officer now owns 106,169 shares of the company's stock, valued at approximately $4,289,227.60. This trade represents a 1.65 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,643 shares of company stock worth $5,256,268. Corporate insiders own 5.80% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on RARE. HC Wainwright reiterated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Canaccord Genuity Group boosted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research note on Friday, December 20th. Wedbush reaffirmed a "neutral" rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $92.79.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded down $1.08 during trading on Tuesday, reaching $31.06. 1,303,794 shares of the company's stock were exchanged, compared to its average volume of 798,406. Ultragenyx Pharmaceutical Inc. has a 1 year low of $30.15 and a 1 year high of $60.37. The stock has a market cap of $2.92 billion, a P/E ratio of -4.90 and a beta of 0.61. The company has a 50 day moving average price of $40.16 and a two-hundred day moving average price of $45.45.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.